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Abstract 
 
         Introduction:  Tramadol is a centrally acting analgesic used for treatment of moderate to 
severe pain. There has been some controversy regarding the dependence lability of long- term 
use  of  this  medication.    The  present  work  was  conducted  to  assess  the  biochemical  toxicity 
profiles of tramadol during therapeutic use. Liver and kidney functions, sex hormones activity 
and some metabolic parameters were studied in male rats.  
         Methods: Rats were divided into three groups. Group one received vehicle (saline), group 
two and three received oral doses of tramadol equal to 40 mg and 80 mg / kg body weight / day 
respectively  for a month followed by 10 days recovery period. Biochemical measurements were 
carried out every 10 days.   
         Results:  There  was  significant  increase  in  the  levels  of  serum  aminotransferases 
(ALT,AST), lactate dehydrogenase (LDH), urea nitrogen (BUN),creatinine and lipid peroxide   
( MDA) in both tramadol groups. In contrast, serum glucose, total cholesterol and triglycerides 
were  significantly  reduced.  Tramadol  significantly  reduced  serum  luteinizing  hormone  (LH), 
follicle stimulating hormone (FSH), testosterone and cortisol, but elevated prolactin (PRL) and 
estradiol (E2) in male rats specially at 20 and 30 days of treatment. After 10 days recovery, 80 
mg tramadol group remained significantly different compared to control one.  
         Conclusion:The present finding pointed out the risk of increased lipid peroxidatin, hepatic 
and renal damage and sexual dysfunction. Tramadol toxic effects should be kept in mind during 
long term therapy specially in large doses.  
 
Introduction 
          
         Tramadol (Tramal 
TM) is a synthetic, 
centrally acting analgesic used parent-erally 
and orally for the treatment of moderate to 
severe  pain.  The  mechanism  of  tramadol 
analgesic  action  is  complex.  Most  reports 
suggest that the analgesic activity and other 
clinical  effects  of  tramadol  are  a  result  of 
opioid  and  non-opioid  mechanisms. 
Tramadol  binds  to  the  μ-opioid  receptor, 
although  much  more  weakly  than 
morphine.  It  also  inhibits  the  neuronal 
reuptake of norepinephrine and serotonin as 
do  the  antidepressant  drugs  such  as 
amitriptyline  and  desimpramine  (Raffa  et 
al., 1992; Raffa, 1996; Dayer et al.,1997; 
Grond and Sablotzki, 2004; Gillman, 2005). 
         Tramadol  has  high  oral  bioavai-
lability in the range of 70- 80%. Peak blood 
levels are reached in about 2 hours after an 
oral dose. The drug is converted in the liver 
to  at  least  one  active  metabolite  (O- 
desmethyl-tramadol: ML), which itself is 2 
to 4 times more potent than tramadol (Wu 
et  al.,  2001;  Tao  et  al.,  2002;  Janssen- 
Ortho  Inc.,  2005).  Its  opioid  activity  is 
greater than the parent compound and could 
contribute  to  this  component  (Lewis  and 
Han,  1997;  Grond  and  Sablotzki,  2004). 
The parent drug and metabolites are mainly 
excreted  via  kidneys  (Matthiessen  et  al., 
1998; Janssen- Ortho Inc., 2005).                                                    
         Tramadol  has  a  dose-  dependent 
analgesic efficacy that lies between that of 
codeine  and  morphine,  with  a  parenteral 
potency comparable to that of pethidine, i.e. 
about  10-  20  %  of  the  standard  morphine 
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(Wilder-  Smith  et  al.,  1999;  Pang  et  al., 
2003).  The  efficacy  of  tramadol  is  not 
associated  with  the  usual  serious  opioid 
side  effects.  Nausea  is  perhaps  the  most 
common side effect and may occur with the 
same  frequency  as  codeine  therapy. 
Dizziness,  constipation  and  headache  have 
been  reported  with  chronic  use  (Cossman 
and Cohnen, 1995). Respiratory depression 
has  not  been  observed,  but  large  doses  of 
tramadol  may  increase  the  respiratory 
effects of other drugs (Houmes et al., 1992; 
Tarkkila et  al.,  1998). Seizures  have  been 
reported in patients receiving recommended 
doses  but  are  more  likely  associated  with 
abuse of this medication (Jick et al., 1998; 
Gasse  et  al.,  2000).  When  seizures  do 
occur, they are commonly of short duration 
and are easily treatable (Spiller et al., 1997; 
Tobias, 1997; Gardner et al., 2000). 
         Unlike nonsteroidal anti-inflammatory 
drugs,  tramadol  has  no  serious  adverse 
gastrointestinal effects such as gut, platelet 
or renal effects of that drug class (Gibson, 
1996; Tolman, 1998). 
         The incidence of abuse of tramadol is 
low  in  all  post-  marketing  surveys;  the 
Food  and  Drug  Administration  reported  a 
rate of abuse in the range of 1 in 100,000 
patient exposures (FDA, 1998). Rare cases 
of  withdrawal  reactions  after  abrupt 
discontinuation  of  tramadol  have  been 
reported (Cossman and Cohnen, 1995). But 
Poison Control data (2002 AAPCC Annual 
Report)  indicated  that  there  were  2,400 
exposures  of  tramadol  reported  to  control 
centers,  of  those,  108  resulted  in  a  major 
medical outcome and 8 resulted in death.  
         Long- term administration of tramadol 
for management of pain, as well as its use 
as an acceptable alternative in persons with 
drug-  seeking  behavior  is  controversial 
(Drugs and Therapy Bulletin, 2002). Also, 
long-  term  effects  of  tramadol  at  cellular 
level,  are  not  clearly  understood  (Atici, 
2005). 
         So, the present work was conducted to 
assess  the  biochemical  toxicity  profiles  of 
this medication (tramadol  HCl) during  one 
month  treatment  and  10  days  recovery 
period.  Liver  and  kidney  functions,  some 
metabolic  parameters  and  sex  hormones 
activity  were  studied  in  male  rats  (Rattus 
norvegicus). 
 
Materials and Methods  
 
Drug: 
         Tramal  (Tramadol  HCl),  50  mg 
capsules, was obtained from Mina- Pharm, 
Egypt.  Its  chemical  name  is  (+)  cis-2- 
[(dimethylamino)methyl]-1-(3-m  ethoxyph-
enyl) cyclohexanol hydrochloride.   
 
Experimental Protocol: 
         110  male  rats  (Rattus  norvegicus) 
weighing 150+5 g were used in the present 
study. All rats were housed in a quite non-
stressful  environment  for  one  week  before 
study.  They  were  given  normal  rat  chows 
ad libitum  during  the  experimental  period. 
They  were  allowed  free  access  to  water. 
Animals  were  divided  into  three  groups. 
The first one was comprised 30 rats, served 
as  control  and  administered  oral  doses  of 
saline solution for a month. The second and 
third groups, each comprised 40 rats, were 
administered  oral  doses  of  tramadol  HCl 
suspended in saline solution equal to 40 mg 
and  80  mg  /Kg  b.  wt.  /day  for  a  month 
respectively.  Ten  rats  from  each  tramadol 
group were left ten days more without any 
additional  treatment  as  a  recovery  period 
after one month exposure. 
Doses  calculated  for  animals  using  Paget 
and  Barnes  (1964)  species  intercoversion 
table of dosage. 
         Control  and  treated  rats  were 
sacrificed at the end of 10, 20, 30, and 40 
days    respectively.  Blood  was  collected  in 
dry  centrifuge  tubes.  Sera  were  separated 
and kept at -20ºC until analysis.  
 
Biochemical Analyses: 
-Alanine  aminotrasferase  (ALT)  and 
Aspartate  aminotransferase  (AST) 
activities  were  measured  using  the 
method of Thomas (1998). 
-Lactate  dehydrogenase  (LDH)  was 
measured  by  the  Scandinavian  assay 
(1974).  
-Creatinine  (Creat.)  was  determined  using 
the method of Fossati et al.(1983). Inass I. El-Gaafarawi 
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-Urea  (BUN)  was  measured  according  to 
Orsonneau et al.(1992). 
-Glucose (Glu.) was determined by Trinder 
(1969) enzymatic method. 
-Total  Cholesterol  (TCh.)  was  determined 
according  to  the  method  of  Flegg 
(1973). 
-Triglycerides (TG.) were measured by the 
method of Fossati and Prencipe (1982). 
-Malondialdhyde (MDA) was measured by 
the method  of Albro  et al.(1986).  The 
amount  of  lipid  peroxides  were 
calculated  as  thio-  barbituric  acid 
reactive  products  of  lipid  peroxidation 
and  reported  as  nmol  of 
malondialdhyde per ml of serum. 
-Luteinizing  hormone  (LH),  follicle 
stimulating  hormone  (FSH),  prolactin 
(PRL),  testosterone  (Tes.),  estradiol 
(E2)  and  cortisol  (Cor.)  were 
determined  using  enzyme  linked 
immunosorbant  assay  (ELISA)  kits 
according to manufacture structure. 
Statistical Analysis:       
All  data  were  expressed  as  means  + 
standard  errors.  Data  of  different  groups 
were  compared  using  Student's  t-  test. 
Differences  at  p<  0.05  were  considered 
significant. 
 
 Results  
 
         Data  in  Table  (1)  showed  that 
administration  of  40  mg  tramadol  /Kg  b. 
wt./day significantly increased serum ALT, 
AST  and  LDH  levels  at  first,  second  and 
third  ten  days  of  treatment  compared  to 
control group (p< 0.05, p< 0.01 and p< 0.01 
respectively).  Also,  BUN  and  creatinine 
were significantly elevated at third ten days 
of  treatment  (p<  0.05)  while,  lipid 
peroxides  (MDA)  increased  gradually  and 
significantly  from  the  first  ten  days 
treatment till one month (p< 0.05, p< 0.01 
and  p<  0.01  respectively).  Glucose,  total 
cholesterol  and  triglycerides  were  reduced 
significantly at 20 and 30 days of treatment 
(p< 0.05 and p< 0.01). On the other hand, 
after ten days recovery period ALT, AST, 
LDH, BUN and creatinine returned to their 
levels, yet did  not reach the  corresponding 
control  group,  except  of    glucose, 
cholesterol,  triglyc-erides  and  MDA  which 
were  significantly  different  from  control 
group (p< 0.05).  
         Results  presented  in  Table  (2) 
indicated  that  administration  of  80  mg 
tramadol  /Kg  b.  wt./day  was  significantly 
induced the  elevation  of ALT,  AST,  LDH 
and  MDA  at  10,  20  and  30  days  of 
treatment  (p<  0.01).  BUN  and  creatinine 
also  increased  at  20  and  30  days  of 
treatment  (p<  0.05  and  p<0.01  respec-
tively).  But  glucose,  total  cholesterol  and 
triglycerides reduced significantly at 20 and 
30 days of treatment (p<0.01) comp-ared to 
control.  The  ten  days  recovery  group 
remained  significantly  different  compared 
to control group. 
         Table (3) showed that 40 mg tramadol 
/Kg  b.  wt.  statistically  elevated  serum  E2 
and  PRL  secretions  with  a  decrease  in 
testosterone levels at 20 days of treatment, 
whereas at 30 days LH, FSH, testosterone 
and  cortisol  were  significantly  reduced 
accompaning with significant increase of E2 
and  PRL  secretions.  After  ten  days 
recovery,  the  measuring  param-eters 
reached  their  normal  levels  except 
testosterone  and  E2  (p<  0.05)  which  still 
recorded  significant  increase  compared  to 
control group. 
         Data in Table (4) revealed that  after 
20  and  30  days  of  treatment  with  80  mg 
tramadol /Kg b. wt., there were significant 
increase in E2  and PRL (p< 0.01) compared 
to  control.  Also,  there  were  higher 
significant  reduction  in  testosterone  and 
cortisol (p< 0.01) accompanied by gradual 
reduction in LH and FSH levels observed at 
20  and  30  days  (p<  0.05  and  p<  0.01 
respectively).  The  recovery  group  was 
noted  to  be  significantly  elevated  over 
corresponding control group. 
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Table  (1):  Effect  of  Tramadol  (40  mg/kg/day)  Administration  on  Biochemical  Profile  of 
Male Rats. 
 
                Conditions 
 
 
Parameters 
Control  Treatment (1 month)  Recovery 
 
X+S.E. 
10 days 
X+S.E. 
20 days 
X+S.E. 
30 days 
X+S.E. 
10 days 
X+S.E. 
ALT(U/L)  35.2+2.0  43.6+1.1*  48.2+1.0**  55.3+0.9**  40.3+1.1 
AST(U/L)  126.4+2.3  143.0+1.4*  188.0+1.2**  203.0+2.6**  130.0+1.2 
LDH(U/L)  556.0+3.2  590.0+2.4*  660.0+2.2**  806.0+3.0**  562.0+1.0 
BUN(mg/dl)  24.2+1.9  25.8+1.0  28.3+1.1  38.0+1.3*  30.4+1.2 
Creat.(mg/dl)  0.4+0.12  0.41+0.1  0.42+0.11  0.56+0.1*  0.43+0.11 
Glu.(mg/dl)  205+2.2  200+2.0  189+1.4*  170+1.9**  186+1.5* 
TCh. (mg/dl)  83.5+2.0  82.0+1.3  70.0+1.0*  62.0+1.0**  75.3+1.3* 
TG. (mg/dl)  92.3+2.2  88.3+1.2  80.0+1.0*  75.0+1.2**  81.5+1.6* 
MDA(nmol/ml)  6.3+1.0  11.9+0.9*  18.2+0.8**  26.0+0.66**  9.2+0.32* 
*=Significant (p< 0.05)             **= Highly significant (p< 0.01) 
Control= The average of the results of control groups were used in the statistical analysis as 
there is no significant difference between them. 
 
Table (2): Effect of Tramadol (80 mg/kg/day) Administration on  Biochemical Profile of 
Male Rats. 
 
                  Conditions 
 
Parameters 
Control  Treatment(1 month)  Recovery 
 
X+S.E. 
10 days 
X+S.E. 
20 days 
X+S.E. 
30 days 
X+S.E. 
10 days 
X+S.E. 
ALT(U/L)  35.2+2.2  53.6+1.4*  64.0+1.6**  69.0+1.3**  49.9+1.3* 
AST(U/L)  126.4+2.3  156.0+2.0*  196.0+1.5**  220.0+2.3**  153.0+2.0* 
LDH(U/L)  556.0+3.2  686.0+2.4**  803.0+3.0**  930.0+2.9**  708.0+2.0* 
BUN(mg/dl)  24.2+1.9  27.0+1.0  39.5+1.0*  50.6+1.3**  32.3+0.9* 
Creat.(mg/dl)  0.4+0.10  0.42+0.1  0.58+0.1*  0.65+0.11**  0.50+0.1* 
Glu.(mg/dl)  205+2.2  195+1.9  176+2.0**  150+1.1**  183+1.3* 
TCh. (mg/dl)  83.5+2.0  80.3+1.3  70.5+1.0**  60.0+1.0**  68.3+1.2* 
TG. (mg/dl)  92.3+2.2  86.0+2.0  73.6+1.3**  62.0+1.0**  80.5+1.2* 
MDA(nmol/ml)  6.3+1.0  16.3+1.1**  20.5+1.2**  35.0+1.1**  19.6+1.0* 
*=Significant (p< 0.05)             **=Highly significant (p< 0.01) 
Control= The average of the results of control groups were used in the statistical analysis as 
there is no significant difference between them. 
 
Table  (3):  Effect  of  Tramadol  (40  mg/kg/day)  Administration  on    Gonadal    Activity  of 
Male Rats. 
 
          Conditions 
 
Parameters 
Control  Treatment (1 month)  Recovery 
 
X+S.E. 
10 days 
X+S.E. 
20 days 
X+S.E. 
30 days 
X+S.E. 
10 days 
X+S.E. 
LH (mlU/ml)  2.25+0.15  2.1+0.11  2.0+0.1  1.4+0.1*  1.9+0.14 
FSH(mlU/ml)  2.0+0.11  2.0+0.1  1.9+0.1  1.0+0.1*  1.65+0.12 
Tes.(ng/ml)  4.0+0.4  3.7+0.2  2.6+0.1*  2.2+0.1**  3.0+0.1* 
E2 (pg/ml)  44.2+1.1  46.5+1.2  51.3+1.0*  61.5+1.2**  52.4+1.1* 
PRL(ng/ml)  6.6+1.0  8.2+0.9  10.0+0.1*  12.9+0.11*  9.0+0.2 
Cor.(ng/ml)  198+2.0  194+1.4  190+1.3  182+1.2*  189.5+1.4 
*=Significant (p< 0.05)             **=Highly significant (p< 0.01) 
Control= The average of the results of control groups were used in the statistical analysis as 
there is no significant difference between them. Inass I. El-Gaafarawi 
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Table  (4):  Effect  of  Tramadol  (80  mg/kg/day)  Administration  on    Gonadol  Activity  of 
Male Rats. 
 
           Conditions 
 
Parameters 
Control  Treatment (1 month)  Recovery 
 
X+S.E. 
10 days 
X+S.E. 
20 days 
X+S.E. 
30 days 
X+S.E. 
10 days 
X+S.E. 
LH (mlU/ml)  2.25+0.15  2.0+0.11  1.3+0.6*  0.92+0.1**  1.4+0.1* 
FSH(mlU/ml)  2.0+0.11  1.9+0.1  1.2+0.01*  0.82+0.01**  1.2+0.1* 
Tes.(ng/ml)  4.0+0.4  3.5+0.1  2.2+0.1**  1.4+0.1**  2.6+0.11* 
E2 (pg/ml)  44.2+1.1  48.5+1.2  62.3+1.0**  73.5+1.6**  55.0+2.0* 
PRL(ng/ml)  6.6+1.0  8.9+1.2  12.6+1.0**  15.3+1.1**  11.7+0.9* 
Cor.(ng/ml)  198+2.0  192+1.6  182+1.3**  177+1.7**  183.0+1.1* 
*=Significant (p< 0.05)             **=Highly significant (p< 0.01) 
Control= The average of the results of control groups were used in the statistical analysis as 
there is no significant difference between them. 
 
 
Discussion 
       
         Hepatic  metabolism  is  a  mechanism 
that  converts  drugs  and  other  compounds 
into products that are more easily excreted 
and  that  usually  have  a  lower  pharmac-
ological activity than the parent compound 
(Tolman,  1998).  A  metabolite  may  have 
higher activity and / or greater toxicity than 
the original drug. Metabolites of the drugs 
that  are  excreted  via  kidneys  may  also 
cause  cellular  damage  leading  to  kidney 
dysfunction (Singhal et al., 1998). 
         The  liver  and  kidney  are  responsible 
for  tramadol  metabolism  and  excretion.  It 
may  cause  hepatotoxicity  and  nephroto-
xicity  during  its  metabolism  (Wu  et  al., 
2001;  Janssen-  Ortho  Inc.,  2005). 
Borzelleca et al. (1994) reported increased 
in  ALT,  AST  and  LDH  activties  in  rats 
after  long-  term  usage  of  morphine-like 
agent  levo-alpha-acetylmethadol  HCl 
(LAAM). Also, a significant increase in the 
levels  of  ALT,  LDH  and  lipid  peroxides 
was  reported  among  chronic  heroin  users 
(Panchenko  et  al.,  1999).  Similarly,  the 
present data was found significant increase 
in the levels of ALT, AST and LDH among 
rats received both doses of tramadol (40 mg 
and 80 mg /Kg b. wt.) with a pronounced 
effect  caused  by  the  large  dose  and  the 
duration of drug administration. 
         On  the  other  hand,  current  results 
indicated  a  slight  increase  in  BUN  and 
creatinine levels in rats received 40 mg /Kg 
tramadol after 30 days treatment but, 80 mg 
/  Kg  tramadol  exerted  moderate  effects  at 
20  and  30  days  treatment.  These  are  in 
accordance  with  Atici  et  al.  (2005)  who 
reported an increase in BUN and creatinine 
levels  in  rats  receiving  morphine  for  a 
month  and  after  long-  term  use  of 
LAAM(Borzelleca et al.,1994). 
         Toxic  effects  of  opioids  at  cellular 
level  may  be  explained  by  lipid  peroxid-
ation.  Biological  membranes  contain  large 
amount  of  poly-unsaturated  fatty  acids, 
which  are  particularly  susceptible  to 
peroxidative attacks by oxidants resulting in 
lipid  peroxidation.  Therefore,  lipid 
peroxidation  has  been  used  as  an  indirect 
marker  of  oxidant-  induced  cell  injury 
(Lurie et al., 1995). A significant increase 
in  lipid  peroxides  was  reported  in  rats 
receiving an acute dose of cocaine (Masini 
et  al.,  1997).  Similarly,  lipid  peroxides 
were  found  significantly  increased  among 
heroin  users  (Panchenko  et  al.,  1999). 
These  findings  are  in  agreement  with  the 
present  results  which  showed  significant 
increase  in  serum  MDA  levels  in  both 
tramadol groups compared to control group, 
indicating an increase in lipid peroxidation. 
         The  current  data  also  revealed 
reduced  levels  of  glucose,  total  cholesterol 
and  triglycerides  in  both  tramadol  groups 
after  20  and  30  days  treatment  with  more 
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supported by a recent study of Cheng et al. 
(2001)  which  showed  that  tramadol  can 
decrease  glycemia  in  diabetic  rats,  via  the 
activation of opioid μ-receptors  suggesting 
a mechanism possibly related to those of 
dextro-propoxyphene   oreover  tramadol 
acts as serotonin reupta e inhibitor  and 
hypoglycemia has been described with 
some serotonin anti-depressants  sertraline 
  eyri re et  al.,  2004).  The  hypoglycemic 
effect  of  Tramacet  (tramadol  containing 
product)  has  been  also  reported  as  a 
metabolic  disorder  that  occurred  as  an 
incidence of less than 1 % in clinical trails  
( Janssen-Ortho Inc., 2005) 
         The reduction of total cholesterol and 
triglycerides  levels  in  the  present  study 
received  evidence  from  El-  Gaafarawi 
(1990) who observed signifi-cant reduction 
in plasma total cholesterol and triglycerides 
levels  after  adminis-tration  of  opioid  and 
non-opioid  analgesics  in  rats.  Also, 
Budzynski et al. (2000) reported reduction 
of serum total cholesterol and triglycerides 
levels in naltraxone (mu- antagonist) treated 
patients. In another study using some antie-
pileptics, Daoud et al. (2004) showed sim-
ilar reduction in serum total cholesterol and 
triglycerides in addition to glucose levels. 
         The  reduction  of  serum  total 
cholesterol  in  the  current  study  supported 
the  reduction  of  testosterone  levels  in  the 
same  study  where,  45%  of  cholesterol 
substrate  for  testosterone  and  sperm 
production  was  derived  from  plasma 
(Connor et al., 1997).  
         Sexual dysfunction  as a  consequence 
of  drug  therapy  has  been  reported  with  a 
range of drugs. About 15% of the 200 most 
commonly  prescribed  drugs  can  have 
adverse  effects  on  male  reproduction  such 
as  sedatives,  tranquilizers,  hypnotics, 
narcotics and cannabis (Chowdhury, 1987), 
antihypertensives,  antipsychotics  and 
antidepressants  (Maclean  and  Lee,  1999). 
Mckim  (2003)  stated  that  opiate  use  is 
known  to  decrease  the  levels  of  sex 
hormones  in  both  sexes  and  this  lowered 
hormonal level is thought to be responsible 
for the diminished fertility of both male and 
female opiate users.    
         In  the  present  study,  gonadal   
examinations  revealed  that  administration 
of tramadol 80 mg /Kg b. wt. for a month 
influenced  sex  hormones  activity  of  male 
rats  at  20  and  30  days  of  treatment 
compared to control group  while, 40 mg  / 
Kg b. wt. tramadol influenced this activity 
to  a  lesser  extent  compared  to  80  mg 
tramadol group and control one. 
         Previous  studies  concerned  with 
gonadal  activity  during  drug  therapy  have 
been  supported  the  present  results. 
Chowdhury  (1987)  reported  decreased 
levels  of  serum  LH  and  testosterone  with 
increased PRL secretion after morphine and 
methadone administration.   Christensen  et 
al.  (1989)  reported  reduction  of  cortisol 
levels  after  3  and  5  weeks  treatment  with 
antidepressants  and  increased  PRL  after 
sertraline adminis-tration  (Broadbear et  al. 
2004).  Also,  Hezog  et  al.  (2004)  reported 
reduced testosterone and elevated E2 levels 
while  Daoud  et  al.  (2004)  reported 
significant  reduction  in  serum  testosterone 
and  FSH  levels  in  antiepileptic  treated 
patients  and  in  rats  respectively.  El- 
Gaafarawi et al.(2005)  have been observed 
in  an  independent  investigation,  the 
reduction  of  serum  levels  of  LH,  FSH, 
testosterone  and  the  induction  of  PRL 
secretion after paroxetine treatment. 
         On  the  other  hand,  the  results  of  10 
days recovery period indicated that most of 
the measured parameters of 40 mg tramadol 
group tended to be some what higher than 
the control group, whereas, 80 mg tramadol 
group  remained  significantly  different 
compared to control one. This may indicate 
that  tramadol  toxic  effects  induced  by 
therapeutic  doses  are  persisted  after  drug 
cessation,  and  the  time  of  recovery  is 
dependent  on  the  concentration  of 
administered dose. 
 
Conclusian 
          
         Tramadol  exerts  its  toxic  effect  via 
two distinct and synergistic mechanisms of 
actions.  This  may  reflect  the  greater 
frequency  of  decreasing  hepatic,  renal  and 
sexual  functions.  Physicians  should  be 
aware  of  aforementioned    adverse  effects 
and  the  glycemic  disturbances  related  to 
tramadol.Dose selection should be cautious.   Inass I. El-Gaafarawi 
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ايميكلا ةيمسلا لودامارتلا راقع ريثات هع ةجتانلا ةيويحلا ةيئ  
ناذرجلا روكذ يف  
 
د  . ىوارفعجلا سانيإ  
ةيئاٌجلا و ةيعاوحجلاا خىحبلل ًهىقلا سكرولا  
   
        دددحبلا الددا ه ددهي     ادد عإ  اردد ج   اددعي  ددك يلددلا ًوددذلا ريذلددحلا نيدديقج ًددلإ
يوي لا  دًاىجلا ادعل ًدلع ىوعادهارحلا  ادقع يده ةديجلاعلا تاعرجلا  يده ةديىيحلا ةديئا
 ادعل و ةديها ٌلا م دنلا تادًىهرا ادعل ضاد ًو نًدل لا و  دب لا وئادظو ةسا ع ىلاخ
 ًئالنلا ليروحلا تلا عه اعل كللك و نلساٌحلا تاًىهرا ( ايلأا  )  ىاذردجلا  ىكذ يى
 اضيبلا .  
         ادهٌه ًدلولأا ثدي عي نىاذردجلا  ىدكذ يده تاعىوجه خلاذ كلذ يى م  حسا  ك و
( ا ةددعىوجولا ة لاددضل  )  ةددرلارلا و ةدديًارلا ةددعىوجولا و نندديلا ودديرض يددع يددحله ىىددلحه
 ىعاعج ىوعاهارحلا يه تاعرج نيلا ويرض يع اضيي ثي عي 04  نندجه 04    ندجه  /  ندجك
يلاىدحلا ًدلع رهدر م دول و اديهىي  نذجلا ىزو يه  .  ىاذردج يده ع دعل ظاديح لاا ندج  دك و
عه يي ىو ددل ةيىادد ي مادديي مردد ع م ددول ييحعىددوجولا ييجاددا  اددقعلال ةددجلا  .  ثدديرجي  ددكو
مايي مر ع لك ةيلوعولا تاسايقلا .  
         تادح للا و زادٌيهي سًارحلا تاويسًإ يه م لا لعه يىححه معايز جئاحٌلا ثح وي
 معاديز ىىا دلل ةديكىيلا م دذكلأا تلا عه معايز كللك و نيييٌيجاير لا و  زاٌيجو  يا يع
ييحعرجلا احل ل ةيىٌعه ةللاع وذ .  
س علا ًلعو  يده م دلا لدعه يىححه ًى ةيىٌعه ةللاع وذ ىاعقً ًلإ ىوعاهارحلا يعي ن
ةيذلارلا ىىا لا و ًل لا ىورحذيلى لاو ر ذلا  .   قى نلساٌحلا تاًىهرا ضا ٌل ةبذٌلال اهي
 تادًىهرا ضاد ً ليلقج ًلإ  نىاحعرجلا تعي FSH,LH     نىوسيج ىد لاو ىوريحدسىحذحلا و
ددسلاا و ييحكلاورددبلا زارددىإ عاز ييدد  ًددى   ددعل ةدد اخو ىاذرددجلا مع لددعه  ًددى ىىيعارح
04  و ن 04   ةجلاعولا يه اهىي .  
         ىوعادهارحلا  ادقع يده ةديجلاعلا تادعرجلا ىاوعحسا ىي ًلإ ةسا  لا ثل ىج  ك و
 و  دب لا وئاظو ًى للخو نىىا لل ةيكىيلا م ذكلأا معايز رضا ه يلإ يعؤي ةليىض م ول
اٌحلا تاددًىهرا ضادد ً ًددى  ار دد ا و نًددل لا  اددعل ًددى ردديينج ًددلإ يعؤددي اددوك نلددس
ايلأا تايلوع  .  معاديز و نماد عولا ةدعرجلا ندج  معاديز زده تاريذلدحلا ٍلا م   عاعسجو
ةجلاعولا مرحى  .   ادقعلا الدهل ةدجلاعولا  دٌع رضاد ولا ٍلدا  ادبحعلاا ًدى لدخلأا  جي الل و
ةليىض مرحيل       .  
 